IQVIA Holdings Inc. (NYSE:IQV – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $272.00 and last traded at $270.9470, with a volume of 425985 shares. The stock had previously closed at $265.67.
Wall Street Analysts Forecast Growth
IQV has been the subject of several recent research reports. Mizuho upped their price objective on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. TD Cowen upped their price target on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Robert W. Baird raised their price target on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a report on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $243.62.
Read Our Latest Report on IQVIA
IQVIA Price Performance
IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the previous year, the company earned $2.81 EPS. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.
Insider Activity
In other news, insider W. Richard Staub sold 5,500 shares of IQVIA stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider directly owned 1,348 shares of the company’s stock, valued at $317,143.96. This represents a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is owned by insiders.
Institutional Trading of IQVIA
Several large investors have recently made changes to their positions in IQV. National Pension Service grew its stake in IQVIA by 6.6% in the second quarter. National Pension Service now owns 375,973 shares of the medical research company’s stock valued at $72,646,000 after acquiring an additional 23,411 shares during the period. WINTON GROUP Ltd acquired a new stake in IQVIA in the 2nd quarter valued at $5,046,000. Engineers Gate Manager LP acquired a new position in IQVIA during the second quarter worth $632,000. SVB Wealth LLC lifted its stake in shares of IQVIA by 7.4% in the second quarter. SVB Wealth LLC now owns 4,349 shares of the medical research company’s stock valued at $840,000 after buying an additional 300 shares in the last quarter. Finally, NewEdge Advisors LLC grew its holdings in shares of IQVIA by 1.2% during the second quarter. NewEdge Advisors LLC now owns 35,788 shares of the medical research company’s stock valued at $6,915,000 after buying an additional 420 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.
About IQVIA
IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.
Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.
Featured Stories
- Five stocks we like better than IQVIA
- Analysts See Double-Digit Upside for These 3 Stocks
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
